SCHEMBL5544329

SCHEMBL5544329

O=[C]OCCCCCCc1cccc(OCCCc2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.49
PPARA Q07869 2/20 0.48
PPARG P37231 1/20 0.48
NAAA Q02083 1/20 0.47
MAOA P21397 3/20 0.46
MAOB P27338 3/20 0.46
FFAR1 O14842 2/20 0.46
ADRB2 P07550 1/20 0.44
PLA2G4B P0C869 1/20 0.44
MTNR1A P48039 1/20 0.44
MTNR1B P49286 1/20 0.44
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.44
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542749 0.90 MGLL (0.61) MGLLPPARAPPARGMAOAMAOB
SCHEMBL5543343 0.90 MGLL (0.61) MGLLPPARAPPARGMAOAMAOB
SCHEMBL5539960 0.89 MGLL (0.59) MGLLMAOAMAOBFFAR1
SCHEMBL5543434 0.87 FFAR1 (0.49) MGLLPPARAPPARGNAAAMAOA
SCHEMBL5536626 0.87 CYP4F2 (0.57) MGLLMAOAMAOBFFAR1
SCHEMBL5545614 0.86 FFAR1 (0.50) MGLLMAOAMAOBFFAR1SIRT2
SCHEMBL5545858 0.85 FFAR1 (0.61) MGLLNAAAFFAR1PLA2G4B
SCHEMBL5541860 0.85 FFAR1 (0.52) MAOAMAOBFFAR1SIRT2
SCHEMBL5534669 0.85 FFAR1 (0.61) MGLLNAAAFFAR1PLA2G4B
SCHEMBL5542297 0.85 FFAR1 (0.61) MGLLNAAAFFAR1PLA2G4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MGLL 4717/4885PPARA 429/4885PPARG 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.